{"keywords": [{"value": "Valeant Pharmaceuticals International Inc", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Philidor Rx Services LLC", "rank": "2", "is_major": "Y", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "rank": "3", "is_major": "Y", "name": "subject"}, {"value": "Pearson, John Michael (1959- )", "rank": "4", "is_major": "Y", "name": "persons"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "5", "is_major": "N", "name": "subject"}, {"value": "Biovail Corp", "rank": "6", "is_major": "N", "name": "organizations"}], "headline": {"kicker": "Op-Ed Columnist", "print_headline": "The Next Enron?", "content_kicker": "Op-Ed Columnist", "main": "Is Valeant Pharmaceuticals the Next Enron?"}, "byline": {"original": "By JOE NOCERA", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "NOCERA", "firstname": "Joe"}]}, "web_url": "http://www.nytimes.com/2015/10/27/opinion/is-valeant-pharmaceuticals-the-next-enron.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "Op-Ed", "_id": "562f25e438f0d82f94187de3", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbWide-v2.png"}, "type": "image", "width": 190, "url": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbWide-v2.png"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbStandard-v2.png"}, "type": "image", "width": 75, "url": "images/2014/11/01/opinion/nocera-circular/nocera-circular-thumbStandard-v2.png"}], "pub_date": "2015-10-27T00:00:00Z", "print_page": "27", "section_name": "Opinion", "word_count": "796", "blog": [], "news_desk": "OpEd", "snippet": "Allegations about Valeant\u2019s practices and its own disclosures while under pressure cause one to wonder.", "document_type": "article", "abstract": "Joe Nocera Op-Ed column welcomes investigation into potentially shady relationship between drug giant Valeant Pharmaceuticals and Philidor; details path of Valeant under chief executive J Michael Pearson and questions integrity of its meteoric rise in stock price.", "lead_paragraph": "Allegations about Valeant\u2019s practices and its own disclosures while under pressure cause one to wonder."}